80 results
Page 4 of 4
8-K
EX-99.1
5wls2h7
13 Apr 21
Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease
9:18am
10-K/A
rxka3r98nttb0u64y
9 Apr 21
Annual report (amended)
4:11pm
10-K
fpyv8mhztf3ydp8f
30 Mar 21
Annual report
4:51pm
8-K
EX-99.1
az88al9ut0f8ovmu 0h
30 Mar 21
Longeveron Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
9:03am
8-K
EX-99.1
6z306t3 el5fm58oee
15 Mar 21
Longeveron Inc. Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
4:30pm
8-K
EX-99.1
vb0z0a23dvu0
9 Mar 21
Longeveron and University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future Collaborations
4:21pm
424B4
76vuw jnef
12 Feb 21
Prospectus supplement with pricing info
4:09pm
FWP
reojyyt4olieap3q de
3 Feb 21
Free writing prospectus
5:01pm
S-1/A
EX-3.1
4z8n2srwh
3 Feb 21
IPO registration (amended)
4:57pm
S-1/A
qd9apxr tb37oo
3 Feb 21
IPO registration (amended)
4:57pm
S-1
rp5mbup 9zrrkknj4
19 Jan 21
IPO registration
5:21pm
S-1
EX-10.4
di124vic54phjjysvcl
19 Jan 21
IPO registration
5:21pm
S-1
EX-10.7
u1sl iot8g
19 Jan 21
IPO registration
5:21pm
DRS/A
kkobtxw pov1
30 Dec 20
Draft registration statement (amended)
12:00am
DRS/A
EX-10.4
acp2lm0mbt7gni
30 Dec 20
Draft registration statement (amended)
12:00am
DRS/A
EX-10.7
ihk2g wcouygx6j
30 Dec 20
Draft registration statement (amended)
12:00am
UPLOAD
0zwbwoewfh93ddm qqgk
10 Dec 20
Letter from SEC
12:00am
DRS
5ugrg73nteesr bfoa9
12 Nov 20
Draft registration statement
12:00am